|
interprofessional education |
40 |
|
social interaction anxiety |
40 |
|
partnership model |
28 |
|
covid-19 |
15 |
|
sars-cov-2 |
13 |
|
construct validation |
12 |
|
heart failure |
10 |
|
anosmia |
9 |
|
olfactory dysfunction |
9 |
|
smell impairment |
9 |
|
acute infection |
7 |
|
convalescent |
7 |
|
dendritic cell |
7 |
|
cardiology |
5 |
|
coronary heart disease |
5 |
|
coronary intervention |
5 |
|
drug escalation |
5 |
|
ischaemic heart disease |
5 |
|
percutaneous coronary intervention |
5 |
|
telemonitoring |
5 |
|
absorb |
4 |
|
extracorporeal membrane oxygenation |
4 |
|
intensive care unit |
4 |
|
mortality |
4 |
|
gastric acid |
3 |
|
gastric cancer |
3 |
|
outcome |
3 |
|
proton pump inhibition |
3 |
|
adolescent |
2 |
|
adult |
2 |
|
all-cause mortality |
2 |
|
analgesia |
2 |
|
anesthesia |
2 |
|
attitude to health |
2 |
|
bare-metal stent |
2 |
|
bioresorbable vascular scaffold |
2 |
|
bioresorbable vascular scaffold; |
2 |
|
bridging |
2 |
|
cannulation |
2 |
|
cardiogenic shock |
2 |
|
credentialing |
2 |
|
crisis resource management |
2 |
|
cross-sectional study |
2 |
|
debriefing |
2 |
|
diabetes |
2 |
|
dipeptidyl peptidase-4 inhibitor |
2 |
|
double lumen cannula |
2 |
|
drug-eluting stent |
2 |
|
dual lumen cannula |
2 |
|
ecmo |
2 |
|
ecmo crisis |
2 |
|
ecpr |
2 |
|
extracorporeal life support (ecls) |
2 |
|
extracorporeal membrane oxygenation (ecmo) |
2 |
|
female |
2 |
|
hemoglobin |
2 |
|
high-fidelity simulation |
2 |
|
human learning |
2 |
|
myocardial strain |
2 |
|
pcrto |
2 |
|
pharmacology |
2 |
|
radial artery catheter |
2 |
|
red blood cell transfusion |
2 |
|
refractory cardiac arrest |
2 |
|
retrograde |
2 |
|
simulation |
2 |
|
sodium-glucose cotransporter 2 inhibitor |
2 |
|
speckle tracking echocardiography |
2 |
|
stroke |
2 |
|
target blood flow |
2 |
|
tolerability |
2 |
|
transthoracic echocardiography |
2 |
|
veno-arterial ecmo |
2 |
|
venoarterial ecls |
2 |
|
venoarterial extracorporeal membrane oxygenation (va ecmo) |
2 |
|
weaning |
2 |
|
28-day mortality |
1 |
|
90-day mortality |
1 |
|
acute kidney injury |
1 |
|
adult intensive & critical care |
1 |
|
aged |
1 |
|
antithrombotic agents |
1 |
|
apache iv |
1 |
|
ards |
1 |
|
atrial fibrillation |
1 |
|
benchmarking |
1 |
|
brain ischemia |
1 |
|
cohort analysis |
1 |
|
cohort study |
1 |
|
delayed emergence from anesthesia |
1 |
|
direct oral anticoagulant |
1 |
|
disease association |
1 |
|
electronic health record |
1 |
|
feasibility study |
1 |
|
hong kong |
1 |
|
icu |
1 |
|
intensive care |
1 |
|
left atrial appendage occlusion |
1 |
|
lung protection ventilation: pressure goal |
1 |
|
major bleeding |
1 |
|
meta-analysis |
1 |
|
neostigmine: dose rationale |
1 |
|
neuromuscular block: assessment |
1 |
|
obesity |
1 |
|
obesity paradox |
1 |
|
overweight |
1 |
|
paradoxical embolism |
1 |
|
patent foramen ovale |
1 |
|
patient care |
1 |
|
pressure‐controlled ventilation |
1 |
|
quality measures |
1 |
|
respiratory infections |
1 |
|
sepsis |
1 |
|
septic shock |
1 |
|
standard mortality ratio |
1 |
|
surgery |
1 |
|
volume‐controlled ventilation |
1 |
